About Tempus AI, Inc. - Class A Common Stock (TEM)
Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry. The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field. Read More
On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc. (NASDAQ:TEM), Coinbase Global Inc. (NASDAQ:COIN), Robinhood Markets Inc. (NASDAQ
Apple's $60 billion cash pile and a rare executive shake-up reignite speculation: will the tech giant finally go on an AI buying spree to catch up with rivals?
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.
PALM BEACH, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global telehealth market has been substantially growing over the past years and is expected to continue this growth well into the future. A report from Grand View Research said that: “The global telehealth market size was estimated at USD 123.26 billion in 2024 and is projected to reach USD 455.27 billion by 2030, growing at a CAGR of 24.68% from 2025 to 2030. North America dominated the telehealth market with the revenue share of 46.58% in 2024. The market is primarily driven by the increasing adoption of digital health & smartphones, rising investments, improved internet connectivity, and growing technological advancements… the growing adoption and acceptance of telehealth services are expected to boost the market's growth over the forecast period.” The report continued: “Moreover, smartphones have evolved from devices of communication & entertainment to devices that can monitor health and fitness. Some market players are developing Chatbot services for basic medical inquiries and one-time consultations… Moreover, the market is propelled by favorable government initiatives to expand telehealth by making healthcare services more accessible and convenient for patients. The focus on cost-effective and efficient healthcare solutions further propels the adoption of telehealth services. The rising adoption of telehealth facilities by patients, physicians, and government authorities is boosting the market. Access to healthcare through specific applications and video consultations enables communication between patients and doctors in remote locations, eliminating the need to visit hospitals or clinics. Market players such as Apple, Google, and IBM focus on improving the mobile health experience by providing numerous solutions through different subscription plans and emphasizing data security. These factors are expected to drive the market growth over the forecast period.” Active tech companies in the markets this week include Treatment AI, Inc. (OTCQB: TREIF) (CSE: TRUE), CVS Health® (NYSE: CVS), Teladoc Health, Inc. (NYSE: TDOC), Tempus AI, Inc. (NASDAQ: TEM), Hims & Hers Health, Inc. (NYSE: HIMS).
NEW ORLEANS, July 09, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
On Wednesday, the Cathie Wood-led Ark Invest made a significant move by purchasing a substantial number of shares in Tempus AI Inc. (NASDAQ:TEM) and selling shares of Block Inc. (NYSE:XYZ).
NEW YORK and NEW ORLEANS, July 08, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of patients across its network of provider sites, helping close critical care gaps for patients with lung cancer. Now, the platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical care to eligible patients.
Cathie Wood's Ark Investment Management has filed plans to launch four new exchange-traded funds designed to offer downside protection for investors in its flagship ARK Innovation ETF (BATS: ARKK), while placing a cap on potential gains.
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW ORLEANS, July 02, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
NEW YORK and NEW ORLEANS, July 01, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the Offering was increased from the previously announced offering size of $400 million.
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), PepGen, Inc. (NASDAQ: PEPG), and Tempus AI, Inc. (NASDAQ: TEM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK CITY, NY / ACCESS Newswire / June 30, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ:TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due in 2030 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Tempus also intends to grant the initial purchasers of the Notes an over-allotment option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $60 million aggregate principal amount of Notes.
